Mexdagry (Metformin Hydrochloride, Dapagliflozin)

Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, while dapagliflozin blocks the renal sodium‑glucose co‑transporter‑2 (SGLT2), causing excess glucose to be excreted in the urine. The dual mechanism reduces overall blood glucose concentrations.

The appropriate dose of Mexdagry is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Mexdagry in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk, and this decision should be made by a qualified clinician.

To order Mexdagry, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mexdagry combines a biguanide (metformin) with an SGLT2 inhibitor (dapagliflozin), offering both insulin‑sensitising and glucose‑excreting effects. Compared with metformin alone, it provides greater HbA1c reduction, and versus SGLT2 inhibitor monotherapy, it adds the benefits of reduced hepatic glucose output.

Mexdagry should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Mexdagry is taken orally, usually as a tablet, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include lactic acidosis, euglycaemic diabetic ketoacidosis, severe dehydration, and hypersensitivity reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, severe abdominal pain, or signs of an allergic reaction.

Mexdagry is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or dapagliflozin, acute or chronic metabolic acidosis, and in those with a history of lactic acidosis. Caution is also advised for patients with hepatic disease or unstable heart failure.